Theratechnologies Inc. (THTX)
USD 1.98
(48.88%)
USD 1.98
(48.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 72.75 Million USD | -22.34% |
| 2022 | 93.68 Million USD | 30.48% |
| 2021 | 71.79 Million USD | 25.72% |
| 2020 | 57.1 Million USD | 25.09% |
| 2019 | 45.65 Million USD | 39.24% |
| 2018 | 32.78 Million USD | 207.03% |
| 2017 | -30.63 Million USD | -82.74% |
| 2016 | -16.76 Million USD | -17.43% |
| 2015 | -14.27 Million USD | -73.88% |
| 2014 | -8.2 Million USD | -810.49% |
| 2013 | -901.69 Thousand USD | 94.69% |
| 2012 | -16.97 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.76 Million USD | 1.6% |
| 2024 Q1 | 12.56 Million USD | -20.04% |
| 2024 Q3 | 11.86 Million USD | -7.06% |
| 2023 Q1 | 20.62 Million USD | -2.82% |
| 2023 Q4 | 15.71 Million USD | -0.75% |
| 2023 Q2 | 20.58 Million USD | -0.18% |
| 2023 FY | 72.75 Million USD | -22.34% |
| 2023 Q3 | 15.83 Million USD | -23.08% |
| 2022 Q4 | 21.22 Million USD | 0.87% |
| 2022 Q2 | -32.79 Million USD | -53.15% |
| 2022 FY | 93.68 Million USD | 30.48% |
| 2022 Q1 | -21.41 Million USD | 3.19% |
| 2022 Q3 | 21.03 Million USD | 164.16% |
| 2021 Q1 | -15.79 Million USD | 5.88% |
| 2021 Q3 | -21.66 Million USD | -19.98% |
| 2021 FY | 71.79 Million USD | 25.72% |
| 2021 Q2 | -18.05 Million USD | -14.31% |
| 2021 Q4 | -22.11 Million USD | -2.08% |
| 2020 Q3 | -15.12 Million USD | 5.77% |
| 2020 FY | 57.1 Million USD | 25.09% |
| 2020 Q1 | -13.58 Million USD | 8.25% |
| 2020 Q2 | -16.04 Million USD | -18.12% |
| 2020 Q4 | -16.78 Million USD | -11.01% |
| 2019 Q2 | -12.87 Million USD | -58.6% |
| 2019 Q4 | -14.8 Million USD | -24.01% |
| 2019 FY | 45.65 Million USD | 39.24% |
| 2019 Q1 | -8.11 Million USD | -4.32% |
| 2019 Q3 | -11.94 Million USD | 7.28% |
| 2018 Q3 | -8.47 Million USD | -12.75% |
| 2018 Q2 | -7.51 Million USD | -12.69% |
| 2018 Q1 | -6.67 Million USD | 16.34% |
| 2018 FY | 32.78 Million USD | 207.03% |
| 2018 Q4 | -7.78 Million USD | 8.2% |
| 2017 Q4 | -7.97 Million USD | -17.9% |
| 2017 Q2 | -10 Million USD | -82.7% |
| 2017 Q1 | -5.47 Million USD | -13.97% |
| 2017 FY | -30.63 Million USD | -82.74% |
| 2017 Q3 | -6.76 Million USD | 32.39% |
| 2016 Q3 | -3.52 Million USD | 19.89% |
| 2016 Q2 | -4.4 Million USD | -5.04% |
| 2016 Q4 | -4.8 Million USD | -36.26% |
| 2016 Q1 | -4.19 Million USD | 5.39% |
| 2016 FY | -16.76 Million USD | -17.43% |
| 2015 FY | -14.27 Million USD | -73.88% |
| 2015 Q4 | -4.42 Million USD | -12.02% |
| 2015 Q1 | -2.97 Million USD | 25.0% |
| 2015 Q3 | -3.95 Million USD | -18.94% |
| 2015 Q2 | -3.32 Million USD | -11.71% |
| 2014 Q1 | -2.12 Million USD | -81.5% |
| 2014 Q2 | 647.4 Thousand USD | 130.44% |
| 2014 Q3 | -2.93 Million USD | -553.28% |
| 2014 Q4 | -3.96 Million USD | -35.23% |
| 2014 FY | -8.2 Million USD | -810.49% |
| 2013 Q3 | -760.25 Thousand USD | 17.83% |
| 2013 Q2 | -925.25 Thousand USD | -146.1% |
| 2013 FY | -901.69 Thousand USD | 94.69% |
| 2013 Q1 | 2 Million USD | 139.17% |
| 2013 Q4 | -1.17 Million USD | -54.12% |
| 2012 Q1 | 3.63 Million USD | 14.86% |
| 2012 Q4 | -5.12 Million USD | -269.02% |
| 2012 Q2 | 3.35 Million USD | -7.68% |
| 2012 Q3 | 3.03 Million USD | -9.72% |
| 2012 FY | -16.97 Million USD | 0.0% |
| 2011 Q2 | 7.5 Million USD | 9.87% |
| 2011 Q4 | 3.16 Million USD | -43.36% |
| 2011 Q1 | 6.83 Million USD | 6.47% |
| 2011 Q3 | 5.59 Million USD | -25.54% |
| 2010 Q3 | 5.07 Million USD | -22.48% |
| 2010 Q2 | 6.54 Million USD | 5.98% |
| 2010 Q1 | 6.17 Million USD | -17.34% |
| 2010 Q4 | 6.42 Million USD | 26.61% |
| 2009 Q3 | 6.68 Million USD | -2.23% |
| 2009 Q1 | 10.05 Million USD | 31.84% |
| 2009 Q2 | 6.83 Million USD | -31.97% |
| 2009 Q4 | 7.46 Million USD | 11.67% |
| 2008 Q3 | 11.23 Million USD | -7.7% |
| 2008 Q1 | 11.69 Million USD | -8.09% |
| 2008 Q2 | 12.16 Million USD | 4.03% |
| 2008 Q4 | 7.62 Million USD | -32.1% |
| 2007 Q2 | 8.27 Million USD | -0.38% |
| 2007 Q3 | 10.33 Million USD | 24.8% |
| 2007 Q1 | 8.3 Million USD | 42.65% |
| 2007 Q4 | 12.72 Million USD | 23.19% |
| 2006 Q3 | 6.93 Million USD | 22.62% |
| 2006 Q1 | 5.2 Million USD | -1.3% |
| 2006 Q2 | 5.65 Million USD | 8.63% |
| 2006 Q4 | 5.82 Million USD | -15.97% |
| 2005 Q1 | 3.79 Million USD | -36.53% |
| 2005 Q3 | 4.6 Million USD | 1.98% |
| 2005 Q4 | 5.27 Million USD | 14.41% |
| 2005 Q2 | 4.51 Million USD | 19.05% |
| 2004 Q3 | 3.71 Million USD | -38.31% |
| 2004 Q1 | 5.9 Million USD | -25.74% |
| 2004 Q2 | 6.01 Million USD | 2.01% |
| 2004 Q4 | 5.98 Million USD | 61.08% |
| 2003 Q3 | 5.51 Million USD | -3.57% |
| 2003 Q4 | 7.94 Million USD | 44.05% |
| 2003 Q2 | 5.72 Million USD | 33.4% |
| 2003 Q1 | 4.28 Million USD | -31.2% |
| 2002 Q4 | 6.23 Million USD | 27.47% |
| 2002 Q1 | 4.88 Million USD | 43.95% |
| 2002 Q2 | 5.11 Million USD | 4.81% |
| 2002 Q3 | 4.88 Million USD | -4.49% |
| 2001 Q1 | 2.38 Million USD | 16.78% |
| 2001 Q4 | 3.39 Million USD | 4.8% |
| 2001 Q3 | 3.23 Million USD | 33.56% |
| 2001 Q2 | 2.42 Million USD | 1.44% |
| 2000 Q1 | 1.58 Million USD | 7.38% |
| 2000 Q2 | 1.86 Million USD | 17.9% |
| 2000 Q3 | 1.53 Million USD | -17.82% |
| 2000 Q4 | 2.04 Million USD | 33.24% |
| 1999 Q4 | 1.47 Million USD | 16.11% |
| 1999 Q3 | 1.27 Million USD | 10.26% |
| 1999 Q1 | 928.07 Thousand USD | 5.46% |
| 1999 Q2 | 1.15 Million USD | 24.23% |
| 1998 Q3 | 1.2 Million USD | -7.83% |
| 1998 Q4 | 880.01 Thousand USD | -26.8% |
| 1998 Q1 | 1.19 Million USD | 23.82% |
| 1998 Q2 | 1.3 Million USD | 9.2% |
| 1997 Q1 | 1.09 Million USD | 0.0% |
| 1997 Q4 | 964.66 Thousand USD | -16.26% |
| 1997 Q2 | 1.52 Million USD | 39.02% |
| 1997 Q3 | 1.15 Million USD | -24.4% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -781.584% |
| Alpha Teknova, Inc. | 45.85 Million USD | -58.652% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 62.876% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -62.206% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 54.301% |
| Cosmos Health Inc. | 26.18 Million USD | -177.898% |
| Journey Medical Corporation | 54.59 Million USD | -33.267% |
| Embecta Corp. | 528.4 Million USD | 86.231% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 73.241% |
| Dynavax Technologies Corporation | 219.14 Million USD | 66.8% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 87.669% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 77.708% |
| PainReform Ltd. | 9.58 Million USD | -659.14% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -454.354% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -454.354% |
| SCYNEXIS, Inc. | 51.84 Million USD | -40.326% |
| Safety Shot Inc | 12.1 Million USD | -500.808% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -2270.529% |
| Procaps Group, S.A. | 199.47 Million USD | 63.527% |
| Harrow Health, Inc. | 89.97 Million USD | 19.136% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -670.231% |
| Biofrontera Inc. | 39.95 Million USD | -82.077% |
| DURECT Corporation | 43.71 Million USD | -66.433% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 86.247% |
| Cronos Group Inc. | 96.7 Million USD | 24.768% |
| OptiNose, Inc. | 85.1 Million USD | 14.507% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 68.656% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -85.825% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 860.966% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 76.839% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -647.685% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -69.041% |
| Radius Health, Inc. | 265.92 Million USD | 72.641% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -425.621% |
| ProPhase Labs, Inc. | 37.85 Million USD | -92.212% |
| Phibro Animal Health Corporation | 260.29 Million USD | 72.049% |
| Procaps Group S.A. | 187.24 Million USD | 61.144% |
| Alvotech | 285.43 Million USD | 74.511% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -640.519% |
| Viatris Inc. | 5.96 Billion USD | 98.781% |
| Rockwell Medical, Inc. | 15.37 Million USD | -373.241% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -21.584% |
| SIGA Technologies, Inc. | 22.04 Million USD | -230.064% |
| Tilray Brands, Inc. | 251.35 Million USD | 71.055% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -48.367% |
| Shineco, Inc. | 17.94 Million USD | -305.37% |
| PetIQ, Inc. | 192.72 Million USD | 62.249% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1722.939% |
| Incannex Healthcare Limited | 30.05 Million USD | -142.092% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 95.443% |
| Alimera Sciences, Inc. | 62.64 Million USD | -16.148% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -9441.871% |
| Assertio Holdings, Inc. | 368.58 Million USD | 80.261% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -1136.176% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -308.546% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -243.691% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -245.764% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 55.896% |
| Hempacco Co., Inc. | 7.59 Million USD | -857.763% |
| Talphera, Inc. | 11.99 Million USD | -506.603% |
| Alvotech | 285.43 Million USD | 74.511% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 48.295% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 78.905% |
| Currenc Group, Inc. | 24 Million USD | -203.124% |
| Kamada Ltd. | 45.42 Million USD | -60.164% |
| Indivior PLC | 911 Million USD | 92.014% |
| Evoke Pharma, Inc. | 12.4 Million USD | -486.286% |
| Flora Growth Corp. | 10.57 Million USD | -587.74% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -245.764% |
| Evolus, Inc. | 189.75 Million USD | 61.659% |
| HUTCHMED (China) Limited | 436.23 Million USD | 83.322% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 52.797% |
| Akanda Corp. | 3.48 Million USD | -1988.584% |